skyrizi solución inyectable 360 mg/ 2.4 ml (risankizumab)
abbvie productos farmacÉuticos ltda. - risankizumab - sin formulas
skyrizi concentrado para solucion para perfusión 600 mg/10 ml (risankizumab)
abbvie productos farmacÉuticos ltda. - risankizumab - sin formulas
skyrizi
abbvie deutschland gmbh & co. kg - risankizumab - psoriasis; arthritis, psoriatic - inmunosupresores - plaque psoriasisskyrizi is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. psoriatic arthritisskyrizi, alone or in combination with methotrexate (mtx), is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (dmards). crohn's diseaseskyrizi is indicated for the treatment of adult patients with moderately to severely active crohn's disease who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy.
skyrizi solución inyectable 150 mg/1 ml (risankizumab)
abbvie productos farmacÉuticos ltda. - risankizumab - sin formulas
skyrizi 75mg /0.83ml solucion inyectable
abbvie sas, sucursal del peru - droguerÍa - risankizumab - solucion inyectable - 75mg/0.83ml - por mililitro 0.83 ml - - risankizumab
skyrizi 150mg / ml solucion inyectable
abbvie sas, sucursal del peru - droguerÍa - risankizumab - solucion inyectable - 150mg / ml - por jeringa precargada 1.00 ml - - risankizumab
skyrizi solución inyectable 75 mg/ 0.83 ml (risankizumab)
abbvie productos farmacÉuticos ltda. - risamkizumab - sin formulas
skyrizi solución inyectable
abbvie deutschland gmbh & co. kg alemania - cada jeringa prellenada contiene: risankizumab 75 mg/0.83 ml - solucion inyectable - cada jeringa prellenada contiene: risankizumab 75 mg/0.83 ml
skyrizi 150 mg/ml solución inyectable
abbvie deutschland gmbh & co. kg alemania - cada jeringa prellenada contiene: risankizumab 150mg/ml - solucion inyectable - cada jeringa prellenada contiene: risankizumab 150mg/ml
diprivan 1% emulsion para inyeccion
emulsion para inyeccion - por mililitro1 ml; propofol 1.000000 g; - risankizumab